http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Carr, Steven A.,Abbatiello, Susan E.,Ackermann, Bradley L.,Borchers, Christoph,Domon, Bruno,Deutsch, Eric W.,Grant, Russell P.,Hoofnagle, Andrew N.,Hü,ttenhain, Ruth,Koomen, John M.,Liebler, Danie The American Society for Biochemistry and Molecula 2014 Molecular and Cellular Proteomics Vol.13 No.3
<P>Adoption of targeted mass spectrometry (MS) approaches such as multiple reaction monitoring (MRM) to study biological and biomedical questions is well underway in the proteomics community. Successful application depends on the ability to generate reliable assays that uniquely and confidently identify target peptides in a sample. Unfortunately, there is a wide range of criteria being applied to say that an assay has been successfully developed. There is no consensus on what criteria are acceptable and little understanding of the impact of variable criteria on the quality of the results generated. Publications describing targeted MS assays for peptides frequently do not contain sufficient information for readers to establish confidence that the tests work as intended or to be able to apply the tests described in their own labs. Guidance must be developed so that targeted MS assays with established performance can be made widely distributed and applied by many labs worldwide. To begin to address the problems and their solutions, a workshop was held at the National Institutes of Health with representatives from the multiple communities developing and employing targeted MS assays. Participants discussed the analytical goals of their experiments and the experimental evidence needed to establish that the assays they develop work as intended and are achieving the required levels of performance. Using this “fit-for-purpose” approach, the group defined three tiers of assays distinguished by their performance and extent of analytical characterization. Computational and statistical tools useful for the analysis of targeted MS results were described. Participants also detailed the information that authors need to provide in their manuscripts to enable reviewers and readers to clearly understand what procedures were performed and to evaluate the reliability of the peptide or protein quantification measurements reported. This paper presents a summary of the meeting and recommendations.</P>
한국인 수혈후 간염과 만성 간질환 환자에서의 C형 간염바이러스 감염동태 (제1보)
정규원 ( Jeong Gyu Won ),선희식 ( Seon Hui Sig ),정환국 ( Jeong Hwan Gug ),신호균 ( Sin Ho Gyun ),박충기 ( Park Chung Gi ),유재영 ( Yu Jae Yeong ),( Adrian M. Di Bisceglie ),( Jeanne J. Waggoner ),( Jay H. Hoofnagle ) 대한내과학회 1990 대한내과학회지 Vol.38 No.6
N/A To investigate the prevalence of antibodies to hepatitis C virus infection in patients with various chronic liver diseases in Korea, we tested 240 serum samples using the Abbott enzyme immunoassay method. The result sare summarized as follows: 1) Among 57 patients with post-transfusion hepatitis(PTH), 38(66.7%) were positive for anti-HCV. Four out of 57 patients were also positive for HBsAg, of which three were positive for anti-HCV. 2) In 131 patients with chronic non-A, non-B hepatitis, who had no history of blood transfusions, 60(45.8%) were positive for anti-HCV; of them 42 out of 85(49.4%) patients with chronic hepatitis, 14 out of 34(41.2%) with liver cirrhosis, and four out of 12(33.3%) with fatty liver and alcoholic hepatitis were positive for anti-HCV. 3) In 27 patients with HBsAg negative hepatocellular carcinoma, 13(48.1%) were positive for anti-HCV. 4) In 25 patients with chronic hepatitis B, who were negative for HBeAg but had active liver disease by liver biopsy, two(8%) were positive for anti-HCV. In conclusion, the prevalence of type C hepatitis in Korea was similar to that of other countries. This test is useful in confirming the diagnosis of various chronic viral hepatitis patients in Korea. Meanwhile, studies of larger numbers of patients and blood donors are necessary to estimate the exact prevalence of this type of hepatitis in Korea.